Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase [5]

Lancet

Volumn 350, Issue 9080, 1997, Pages 784-

  Riemenschneider, M ^a   Buch, K ^b   Schmolke, M ^b   Kurz, A ^b   Guder, W G ^b  

^a Institute of Clinical Chemistry   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; MARKER; MICROTUBULE ASSOCIATED PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; EXTRACELLULAR SPACE; GLUCOSE METABOLISM; HUMAN; LETTER; NERVE CELL DEGENERATION; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0342327317     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62568-8     Document Type: Article

References (4)

1. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996; 212: 209-11.
2. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early onset dementia of Alzheimer type. J Neural Transm 1989; 75: 227-32.
3. Katzman R, Fishman R, Goldensohn E. Glutamic-oxalacetic transminase activity in spinal fluid. Neurology 1957; 8: 853-55.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.